Oyama Jun-Ichi, Higashi Yukihito, Node Koichi
Department of Cardiovascular Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan.
Cardiovasc Diabetol. 2014 Jan 15;13:21. doi: 10.1186/1475-2840-13-21.
An impaired endothelial function has been recognized in the early stage of atherosclerosis, and is a major factor affecting the future development of cardiovascular events. Type 2 diabetes mellitus (T2DM) is widely prevalent, and is one of the most important risk factors for cardiovascular disease. T2DM is associated with increases in both morbidity and mortality, particularly from cardiovascular disease.New therapies based on the incretin hormone and its actions are now becoming widely used, and appear to offer advantages over conventional therapies by keeping the body weight steady and limiting hypoglycemia, while also achieving attractive glycemic control. However, there is little data available about the effects of incretins on the cardiovascular system.This review will focus on the effects of incretin therapies, including glucagon-like peptide-1 (GLP-1) analogs and dipeptidyl peptidase (DPP)-4 inhibitors, on the endothelial function, and will discuss the potential mechanisms underlying these effects.
内皮功能受损在动脉粥样硬化早期就已被认识到，并且是影响心血管事件未来发展的主要因素。2型糖尿病（T2DM）广泛流行，是心血管疾病最重要的危险因素之一。T2DM与发病率和死亡率的增加相关，尤其是心血管疾病导致的发病率和死亡率。基于肠促胰岛素激素及其作用的新疗法目前正在广泛应用，并且似乎比传统疗法具有优势，能够保持体重稳定、限制低血糖，同时实现有吸引力的血糖控制。然而，关于肠促胰岛素对心血管系统影响的数据很少。本综述将聚焦于肠促胰岛素疗法，包括胰高血糖素样肽-1（GLP-1）类似物和二肽基肽酶（DPP）-4抑制剂，对内皮功能的影响，并将讨论这些影响背后的潜在机制。
